Evidence map›Paper›PMID 41198972›Full record

ArticleAAPS PharmSciTech2025

The Influence of pH and Preservative Agents on Physicochemical and Microbiological Stability of a Flexible Dose/Age-Appropriate Formulation of Enalapril Maleate. A Quality by Design‑Based Optimization.

Mauro Morri, María Alejandra Operto, Rubén Maggio, Darío Leonardi, Silvana Vignaduzzo

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mauro MorriPlanta Piloto de Producción de Medicamentos, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 570, 2000, Rosario, Argentina.
María Alejandra OpertoDepartamento Química Orgánica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Área Análisis de Medicamentos, Universidad Nacional de Rosario, Suipacha 531, S2002LRK, Rosario, Argentina.
Rubén MaggioDepartamento Química Orgánica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Área Análisis de Medicamentos, Universidad Nacional de Rosario, Suipacha 531, S2002LRK, Rosario, Argentina.
Darío LeonardiIQUIR-CONICET, Suipacha 570, S2002LRK, Rosario, Argentina. leonardi@iquir-conicet.gov.ar.ORCID http://orcid.org/0000-0003-2292-3570
Silvana VignaduzzoDepartamento Química Orgánica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Área Análisis de Medicamentos, Universidad Nacional de Rosario, Suipacha 531, S2002LRK, Rosario, Argentina. svignadu@fbioyf.unr.edu.ar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enalapril (ENA) is indicated for the management of heart failure, hypertension, and asymptomatic left ventricular dysfunction, while pediatric patients also benefit from its use in treating hypertension and congestive heart failure. ENA is commercially available as tablets with doses ranging from 2.5 to 20 mg. However, achieving the typical starting dose of 0.1 mg kg

Indexed as

EnalaprilPreservatives, PharmaceuticalAdministration, OralChemistry, PharmaceuticalDrug CompoundingDrug StabilityHumansHydrogen-Ion ConcentrationTabletsEnalaprilPreservatives, PharmaceuticalTabletsCritical process parametersCritical quality attributesDesign of experimentsEnalapril maleateLiquid formulationQuality by designQuality target product profiles

Identifiers

PMID41198972

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.